Optimal glycemic control with minimal hypo- and hyperglycemia in type 1 diabetes (T1D) is difficult to achieve. New technologies such as hybrid closed loop (HCL-670G) system could help to improve glycemic control and prevent complications. We report a single-center 6-month experience regarding changes in metrics for glycemic control in adult patients with T1D on the Medtronic® 670G system. There were 139 patients (mean±SD age 41±12 years, 60% women) with T1D who were on a pump and CGM for at least 3 months prior to initiating 670G system, and who had at least six months of follow-up on 670G. We analyzed the changes in HbA1c, daily insulin dose, and BMI from baseline (just prior to initiating 670G system) at 3 and 6-months of 670G use. The mean percent time in auto-mode was 71% at 3 months and 73% at 6 months, with a range of 0-99% at both time points. Use of the 670G system significantly improved HbA1c with no change in BMI (Table). Percent time in auto-mode was significantly correlated to HbA1c at 3 (r=-0.26, p=0.009) and 6 months (r=-0.32, p=0.002). Daily bolus and total insulin dose increased at 3 months but were not significantly higher than pre-670G after 6 months of 670G use. We conclude that HCL use in real-life improves glucose control without increasing body weight or insulin dose.


D.A. Giordano: None. J.K. Snell-Bergeon: None. H. Joseph: None. S.K. Garg: Advisory Panel; Self; Eli Lilly and Company, Roche Pharma, Sanofi-Aventis, Zealand Pharma A/S. Research Support; Self; Eli Lilly and Company, WebMD. H.K. Akturk: Advisory Panel; Self; Sanofi. Research Support; Self; Eli Lilly and Company, MannKind Corporation, REMD Biotherapeutics. Speaker's Bureau; Self; MannKind Corporation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.